Title
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
Date Issued
01 September 2012
Access level
open access
Resource Type
journal article
Author(s)
Hanly J.G.
Urowitz M.B.
Su L.
Gordon C.
Bae S.C.
Sanchez-Guerrero J.
Romero-Diaz J.
Wallace D.J.
Clarke A.E.
Ginzler E.M.
Merrill J.T.
Isenberg D.A.
Rahman A.
Petri M.
Fortin P.R.
Gladman D.D.
Bruce I.N.
Steinsson K.
Dooley M.A.
Khamashta M.A.
Fessler B.J.
Ramsey-Goldman R.
Manzi S.
Zoma A.A.
Sturfelt G.K.
Nived O.
Aranow C.
Mackay M.
Ramos-Casals M.
Van Vollenhoven R.F.
Kalunian K.C.
Ruiz-Irastorza G.
Lim S.
Kamen D.L.
Peschken C.A.
Inanc M.
Theriault C.
Thompson K.
Farewell V.
Info Heersink School of Medicine
Abstract
Objective: The aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE). Methods: The Systemic Lupus International Collaborating Clinics, or SLICC, performed a prospective inception cohort study. Demographic variables, global SLE disease activity (SLE Disease Activity Index 2000), cumulative organ damage (SLICC/American College of Rheumatology Damage Index (SDI)) and neuropsychiatric events were recorded at enrolment and annually. Lupus anticoagulant, anticardiolipin, anti-β 2glycoprotein-I, antiribosomal P and anti-NR2 glutamate receptor antibodies were measured at enrolment. Physician outcomes of seizures were recorded. Patient outcomes were derived from the SF-36 (36-Item Short Form Health Survey) mental component summary and physical component summary scores. Statistical analyses included Cox and linear regressions. Results: The cohort was 89.4% female with a mean follow-up of 3.5±2.9 years. Of 1631 patients, 75 (4.6%) had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a higher risk of seizures with African race/ethnicity (HR (CI): 1.97 (1.07 to 3.63); p=0.03) and lower education status (1.97 (1.21 to 3.19); p<0.01). Higher damage scores (without neuropsychiatric variables) were associated with an increased risk of subsequent seizures (SDI=1:3.93 (1.46 to 10.55); SDI=2 or 3:1.57 (0.32 to 7.65); SDI≥4:7.86 (0.89 to 69.06); p=0.03). There was an association with disease activity but not with autoantibodies. Seizures attributed to SLE frequently resolved (59/78 (76%)) in the absence of antiseizure drugs. There was no significant impact on the mental component summary or physical component summary scores. Antimalarial drugs in the absence of immunosuppressive agents were associated with reduced seizure risk (0.07 (0.01 to 0.66); p=0.03). Conclusion: Seizures occurred close to SLE diagnosis, in patients with African race/ethnicity, lower educational status and cumulative organ damage. Most seizures resolved without a negative impact on health-related quality of life. Antimalarial drugs were associated with a protective effect.
Start page
1502
End page
1509
Volume
71
Issue
9
Language
English
OCDE Knowledge area
Epidemiología Inmunología Reumatología
Scopus EID
2-s2.0-84864868783
PubMed ID
Source
Annals of the Rheumatic Diseases
ISSN of the container
14682060
DOI of the container
10.1136/annrheumdis-2011-201089
Source funding
National Center for Research Resources
Sources of information: Directorio de Producción Científica Scopus